Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PNT - POINT Biopharma Global Inc

IEX Last Trade
12.51
12.510   100.000%

Share volume: 0
Last Updated: Tue 26 Dec 2023 09:07:44 PM CET
Pharmaceutical Preparation Manufacturing : 2.74%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
39%
Profitability 8%
Dept financing 7%
Liquidity 75%
Performance 70%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
84.09%
Key data
Stock price
$12.51
P/E Ratio 
24.32
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
N/A - N/A
52 WEEK CHANGE
N/A
MARKET CAP 
16.147 B
YIELD 
0.93%
SHARES OUTSTANDING 
105.683 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.26
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Joe McCann
Region: US
Website: pointbiopharma.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

POINT Biopharma Global Inc. focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioliand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the. treatment of non-metastatic. castration sensitive prostate cancer, which is under study.

Recent news